RU2328308C2 - Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета - Google Patents

Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета Download PDF

Info

Publication number
RU2328308C2
RU2328308C2 RU2003103436/15A RU2003103436A RU2328308C2 RU 2328308 C2 RU2328308 C2 RU 2328308C2 RU 2003103436/15 A RU2003103436/15 A RU 2003103436/15A RU 2003103436 A RU2003103436 A RU 2003103436A RU 2328308 C2 RU2328308 C2 RU 2328308C2
Authority
RU
Russia
Prior art keywords
alkyl
aryl
group
aralkyl
alicyclic
Prior art date
Application number
RU2003103436/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003103436A (ru
Inventor
ПУЛЬЕ Пауль Д. ВАН (US)
ПУЛЬЕ Пауль Д. ВАН
Марк Д. ЭРИОН (US)
Марк Д. ЭРИОН
Тосихико ФУДЗИВАРА (JP)
Тосихико Фудзивара
Original Assignee
Метабэйсис Терапьютикс, Инк.
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метабэйсис Терапьютикс, Инк., Санкио Компани, Лимитед filed Critical Метабэйсис Терапьютикс, Инк.
Publication of RU2003103436A publication Critical patent/RU2003103436A/ru
Application granted granted Critical
Publication of RU2328308C2 publication Critical patent/RU2328308C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2003103436/15A 2000-07-06 2001-07-05 Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета RU2328308C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
US60/216,531 2000-07-06

Publications (2)

Publication Number Publication Date
RU2003103436A RU2003103436A (ru) 2004-06-27
RU2328308C2 true RU2328308C2 (ru) 2008-07-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003103436/15A RU2328308C2 (ru) 2000-07-06 2001-07-05 Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета

Country Status (18)

Country Link
EP (1) EP1372660A2 (fr)
JP (1) JP2004508297A (fr)
KR (1) KR100854851B1 (fr)
CN (2) CN100396283C (fr)
AU (2) AU2001273271B2 (fr)
BR (1) BR0112212A (fr)
CA (1) CA2412142A1 (fr)
CZ (1) CZ20035A3 (fr)
HU (1) HUP0301830A3 (fr)
IL (2) IL153513A0 (fr)
MX (1) MXPA02012713A (fr)
NO (1) NO20030034L (fr)
NZ (1) NZ523227A (fr)
PL (1) PL365779A1 (fr)
RU (1) RU2328308C2 (fr)
SK (1) SK62003A3 (fr)
WO (1) WO2002003978A2 (fr)
ZA (1) ZA200300044B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664422C2 (ru) * 2012-10-08 2018-08-17 ЭлДжи КЕМ, ЛТД. Комбинированный препарат, содержащий гемиглиптин и метформин, и способ его получения

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
JP2002524463A (ja) 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
MXPA02008722A (es) 2000-03-08 2004-05-05 Metabasis Therapeutics Inc Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
KR100989647B1 (ko) 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
WO2003057235A2 (fr) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification des habitudes alimentaires
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PT1700856E (pt) 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
CN101119748A (zh) * 2004-12-13 2008-02-06 第一三共株式会社 用于治疗糖尿病的药物组合物
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (fr) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Préparation obtenue par voie sèche
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114474T1 (de) * 1989-01-24 1994-12-15 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
WO1998039342A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
WO1998039344A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
JP2002524463A (ja) * 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
AU771039B2 (en) * 1998-12-24 2004-03-11 Metabasis Therapeutics, Inc. A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
DK1741445T3 (da) * 2000-01-21 2013-11-04 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664422C2 (ru) * 2012-10-08 2018-08-17 ЭлДжи КЕМ, ЛТД. Комбинированный препарат, содержащий гемиглиптин и метформин, и способ его получения

Also Published As

Publication number Publication date
CN1599612A (zh) 2005-03-23
AU2001273271B2 (en) 2006-01-05
ZA200300044B (en) 2004-05-06
CA2412142A1 (fr) 2002-01-17
WO2002003978A2 (fr) 2002-01-17
NO20030034D0 (no) 2003-01-03
KR20030031952A (ko) 2003-04-23
NZ523227A (en) 2005-04-29
CN100396283C (zh) 2008-06-25
IL153513A (en) 2014-07-31
KR100854851B1 (ko) 2008-08-27
NO20030034L (no) 2003-03-05
MXPA02012713A (es) 2004-09-10
IL153513A0 (en) 2003-07-06
PL365779A1 (en) 2005-01-10
CN101301294A (zh) 2008-11-12
JP2004508297A (ja) 2004-03-18
CZ20035A3 (cs) 2003-05-14
SK62003A3 (en) 2003-09-11
HUP0301830A3 (en) 2007-10-29
BR0112212A (pt) 2003-12-30
WO2002003978A3 (fr) 2003-10-16
HUP0301830A2 (hu) 2003-11-28
AU7327101A (en) 2002-01-21
EP1372660A2 (fr) 2004-01-02

Similar Documents

Publication Publication Date Title
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
RU2328308C2 (ru) Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
ES2246586T3 (es) Una combinacion de inhibidores de fbpasa y sensibilizantes de insulina para el tratamiento de la diabetes.
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
KR100818845B1 (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
KR20020079988A (ko) 신규한 아릴 프럭토스-1,6-비스포스파타제 억제제
LV12686A (en) Method for treating diabetes employing an ap2 inhibitor and combination
US20100056460A1 (en) Combination of organic compounds
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1552850A2 (fr) Combinaisons d'inhibiteurs de la FBPase et de sensibilisateurs à l'insuline, pour le traitement du diabète
ERION QUN DANG*, PAUL D. VAN POELJE AND

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC4A Invention patent assignment

Effective date: 20080911

MM4A The patent is invalid due to non-payment of fees

Effective date: 20100706

MM4A The patent is invalid due to non-payment of fees

Effective date: 20180706